Clinical Management for Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorders

Overview

Journal J Clin Exp Hematop

Specialties Hematology
Pathology

Date 2019 Jul 2

PMID 31257348

Citations 37

Authors

Michihide Tokuhira

Jun-Ichi Tamaru

Masahiro Kizaki

Affiliations

Soon will be listed here.

Abstract

Other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD), a category of immunodeficiency-associated LPD according to the World Health Organization classification, is associated with immunosuppressive drugs (ISDs). Several factors, including autoimmune disease (AID) activity, Epstein-Barr virus (EBV) infection, ISD usage, and aging, influence the development of OIIA-LPD, resulting in complicated clinical courses and outcomes. Most OIIA-LPD develops in patients with rheumatoid arthritis using methotrexate (MTX-LPD). The management of MTX-LPD is based on the clinical course, i.e., with/without regression, with/without relapse/regrowth event (RRE), LPD subtype, and ISDs for AIDs after LPD development. There are three clinical courses after ISD withdrawal: regressive LPD without relapse/regrowth (R-G), regressive LPD with RRE (R/R-G), and persistent LPD (P-G). The majority of EBV+ diffuse large B-cell lymphomas are classified in R-G, whereas classic Hodgkin lymphoma is generally classified in R/R-G. Polymorphic LPD (P-LPD) in MTX-LPD develops with heterogeneous pathological features similar to monomorphic LPD. Chemotherapy for MTX-LPD is selected according to that for de novo LPD, although the strategy for aggressive P-LPD and non-specific LPD is not well established. The absolute lymphocyte count in the peripheral blood has been suggested as a candidate marker for MTX-LPD development and RRE. Several clinical issues, including correct diagnosis among overlapping clinicopathological features in MTX-LPD and clinical management of LPD by ISDs other than MTX, require further investigation.

Citing Articles

Treatment of Methotrexate-Associated Lymphoproliferative Disorder With Biological Therapies.

Afu K, Durkee A Cureus. 2025; 17(1):e76751.

PMID: 39897234 PMC: 11785414. DOI: 10.7759/cureus.76751.

A Review of the Impact of Sjögren's Syndrome and/or the Presence of Anti-Ro/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis.

Horai Y, Kurushima S, Shimizu T, Nakamura H, Kawakami A J Clin Med. 2025; 14(2).

PMID: 39860574 PMC: 11766391. DOI: 10.3390/jcm14020568.

Successful Treatment of Methotrexate-associated Lymphoproliferative Disorder with the Pola-R-CHP Regimen.

Seki H, Morita K, Yamazaki S, Kurokawa M Intern Med. 2025; 64(1):123-127.

PMID: 39757000 PMC: 11781930. DOI: 10.2169/internalmedicine.3634-24.

Hepatic methotrexate-associated lymphoproliferative disease: a case report and literature review.

Sakamoto S, Tabuchi M, Yoshimatsu R, Matsumoto M, Iwata J, Okabayashi T Surg Case Rep. 2024; 10(1):260.

PMID: 39542926 PMC: 11564438. DOI: 10.1186/s40792-024-02065-8.

Methotrexate‑associated B‑cell lymphoproliferative disease that exhibits hematuria due to urinary bladder lesions: A case report.

Manabe M, Nagano Y, Okuno T, Inoue T, Koh K Med Int (Lond). 2024; 4(4):44.

PMID: 38912416 PMC: 11190731. DOI: 10.3892/mi.2024.168.

References

Toussirot E, Wendling D, Tiberghien P, Luka J, Roudier J . Decreased T cell precursor frequencies to Epstein-Barr virus glycoprotein Gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis. Ann Rheum Dis. 2000; 59(7):533-8. PMC: 1753187. DOI: 10.1136/ard.59.7.533. View

Stevens S, Verschuuren E, Pronk I, van der Bij W, Harmsen M, The T . Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001; 97(5):1165-71. DOI: 10.1182/blood.v97.5.1165. View

Boulanger E, Rieux-Laucat F, Picard C, Legall M, Sigaux F, Clauvel J . Diffuse large B-cell non-Hodgkin's lymphoma in a patient with autoimmune lymphoproliferative syndrome. Br J Haematol. 2001; 113(2):432-4. DOI: 10.1046/j.1365-2141.2001.02749.x. View

Wagner H, Wessel M, Jabs W, Smets F, Fischer L, Offner G . Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation. 2001; 72(6):1012-9. DOI: 10.1097/00007890-200109270-00006. View

Baird R, van Zyl-Smit R, Dilke T, Scott S, Rassam S . Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br J Haematol. 2002; 118(2):567-8. DOI: 10.1046/j.1365-2141.2002.03619.x. View

Lim I, Bertouch J . Remission of lymphoma after drug withdrawal in rheumatoid arthritis. Med J Aust. 2002; 177(9):500-1. DOI: 10.5694/j.1326-5377.2002.tb04919.x. View

Balandraud N, Meynard J, Auger I, Sovran H, Mugnier B, Reviron D . Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 2003; 48(5):1223-8. DOI: 10.1002/art.10933. View

Ebeo C, Girish M, Byrd R, Roy T, Mehta J . Methotrexate-induced pulmonary lymphoma. Chest. 2003; 123(6):2150-3. DOI: 10.1378/chest.123.6.2150. View

Hoshida Y, Tomita Y, Zhiming D, Yamauchi A, Nakatsuka S, Kurasono Y . Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer. 2003; 108(3):443-9. DOI: 10.1002/ijc.11582. View

10.

Feng W, Cohen J, Fischer S, Li L, Sneller M, Goldbach-Mansky R . Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004; 96(22):1691-702. DOI: 10.1093/jnci/djh313. View

11.

Lelievre J, Sacre K, Adle-Biassette H, Molinier-Frenkel V, Gaulard P, Papo T . Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression. J Am Acad Dermatol. 2005; 52(2 Suppl 1):24-7. DOI: 10.1016/j.jaad.2004.06.043. View

12.

Kojima M, Motoori T, Hosomura Y, Tanaka H, Sakata N, Masawa N . Atypical lymphoplasmacytic and immunoblastic proliferation from rheumatoid arthritis: a case report. Pathol Res Pract. 2005; 202(1):51-4. DOI: 10.1016/j.prp.2005.10.005. View

13.

Svensson A, Jacobson E, Ospina D, Tindle B . Reversible Epstein-Barr virus-negative lymphadenopathy and bone marrow involved by Hodgkin's lymphoma in a rheumatoid arthritis patient undergoing long-term treatment with low-dose methotrexate: a case report and review of the literature. Int J Hematol. 2006; 83(1):47-50. DOI: 10.1532/IJH97.NA0503. View

14.

Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F . Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54(3):692-701. DOI: 10.1002/art.21675. View

15.

Kojima M, Itoh H, Hirabayashi K, Igarashi S, Tamaki Y, Murayama K . Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. Pathol Res Pract. 2006; 202(9):679-85. DOI: 10.1016/j.prp.2006.05.007. View

16.

Clarke L, Junkins-Hopkins J, Seykora J, Adler D, Elenitsas R . Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. J Am Acad Dermatol. 2006; 56(4):686-90. DOI: 10.1016/j.jaad.2006.09.011. View

17.

Balandraud N, Guis S, Meynard J, Auger I, Roudier J, Roudier C . Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 2007; 57(5):762-7. DOI: 10.1002/art.22783. View

18.

Ogasawara T, Kimura A, Yasuyama M, Ohtuka K, Aiba M, Kawauchi K . [2-year complete remission after withdrawal of methotrexate in a rectal methotrexate-associated diffuse large B-cell lymphoma]. Rinsho Ketsueki. 2007; 48(6):485-90. View

19.

Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K . Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007; 82(12):1106-9. DOI: 10.1002/ajh.21003. View

20.

Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y . Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007; 13(17):5124-32. DOI: 10.1158/1078-0432.CCR-06-2823. View